HIV Protease antibody
-
- Target
- HIV Protease
-
Reactivity
- Human Immunodeficiency Virus (HIV)
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- Un-conjugated
-
Application
- ELISA, Western Blotting (WB)
- Specificity
- The antibody 1696 recognizes free N-terminus of mature HIV protease (HIV-1 and HIV-2), an enzyme that hydrolyzes polyproteins of HIV viruses into functional proteins. The antibody 1696 does not react with the precursor.
- Cross-Reactivity (Details)
- HIV
- Purification
- Purified by protein-A affinity chromatography.
- Purity
- > 95 % (by SDS-PAGE)
- Immunogen
- Bacterially expressed full-length HIV-1 protease
- Clone
- 1696
- Isotype
- IgG1
-
-
- Application Notes
- Western blotting: Recommended dilution: 0.5 μg/mL.
- Restrictions
- For Research Use only
-
- Concentration
- 1 mg/mL
- Buffer
- Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
- Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Handling Advice
- Do not freeze.
- Storage
- 4 °C
- Storage Comment
- Store at 2-8°C. Do not freeze.
-
-
Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity." in: Vaccine, Vol. 29, Issue 4, pp. 839-48, (2011) (PubMed).
: "Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies." in: Antiviral research, Vol. 78, Issue 3, pp. 275-7, (2008) (PubMed).
: "Diversification and specialization of HIV protease function during in vitro evolution." in: Molecular biology and evolution, Vol. 23, Issue 4, pp. 764-72, (2006) (PubMed).
: "Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody." in: Protein science : a publication of the Protein Society, Vol. 8, Issue 12, pp. 2686-96, (2000) (PubMed).
: "
-
Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity." in: Vaccine, Vol. 29, Issue 4, pp. 839-48, (2011) (PubMed).
-
- Target
- HIV Protease
- Target Type
- Viral Protein
- Background
- The HIV protease (PR) hydrolyzes polyproteins of HIV virus into functional protein products that are essential for its assembly and subsequent activity. This maturation process occurs as the virion buds from the host cell. HIV protease inhibitors are used in the treatment of patients with AIDS and were considered the first breakthrough in over a decade of AIDS research. HIV protease inhibitors can lower the viral load carried by AIDS patents.,HIV-1 PR, HIV-2 PR
-